Can Drugs Cause Diabetes? Medications That Increase Your Risk

Dozens of widely prescribed medications can raise blood sugar, and some push people into full-blown diabetes. Glucocorticoids, certain antipsychotics, statins, blood pressure drugs, immunosuppressants, and HIV medications are among the best-documented offenders. Whether a given drug tips you over the edge depends on the dose, how long you take it, and how vulnerable your metabolism already is. The interplay between drug effects and individual risk factors makes this a more nuanced problem than most people realize.

Glucocorticoids Are the Most Common Culprits

If one drug class stands out for causing diabetes, it is glucocorticoids, the family of steroids that includes prednisone, dexamethasone, and methylprednisolone. These drugs are workhorses in medicine, used for everything from asthma and autoimmune diseases to organ transplant rejection. But they drive insulin resistance throughout the body and interfere with how your tissues handle fat and sugar.

The numbers vary depending on who is being treated and how much steroid they are getting. A meta-analysis found that roughly a third of patients on glucocorticoids developed abnormally high blood sugar, while about 19% met the threshold for diabetes itself. In organ transplant patients receiving steroid-heavy regimens, abnormal glucose metabolism has been reported in 17% to 32% of cases. Among hospitalized patients without a prior history of diabetes, blood sugar above 200 mg/dL occurred in over half of those given corticosteroids.

1Endocrinology and Metabolism. Glucocorticoid-Induced Diabetes Mellitus: An Important but Overlooked Problem

A study of 231 patients with respiratory diseases found that about 15% developed steroid-induced diabetes, with older age emerging as the strongest independent risk factor.

2PubMed Central. Incidence and risk factors of steroid-induced diabetes in patients with respiratory disease

The dose, the potency of the steroid, and how long you stay on it all matter. A short burst of prednisone for a flare-up carries far less risk than months of high-dose therapy after a transplant. But even short courses can temporarily spike blood sugar high enough to cause problems in someone who is already prediabetic. That is why guidelines recommend checking blood sugar in anyone started on moderate to high doses of glucocorticoids, especially if they have other risk factors like obesity or a family history of diabetes.

3Acta Medica. Management of glucocorticoid-induced diabetes

Statins and the Diabetes Tradeoff

Statins are among the most prescribed drugs on the planet, and their cardiovascular benefits are well established. But there is a real and dose-dependent increase in diabetes risk that comes along with them. A large meta-analysis of randomized trials found that low-to-moderate-intensity statin therapy raised the rate of new diabetes diagnoses by about 10%, while high-intensity therapy raised it by about 36%.

4The Lancet. Efficacy and safety of statin therapy in relation to glycaemia: a meta-analysis of individual participant data from randomised controlled trials

The risk is not just about how strong the statin is. Duration matters too. A nationwide observational study found that the hazard of developing diabetes roughly doubled after one to two years of statin use and continued climbing beyond that. Higher cumulative doses carried a steeper risk as well.

5PubMed Central. Time- and Dose-Dependent Association of Statin Use With Risk of Clinically Relevant New-Onset Diabetes Mellitus in Primary Prevention

The mechanism involves both decreased insulin sensitivity and reduced insulin secretion. One study estimated that statin users had about 24% lower insulin sensitivity and 12% lower insulin secretion compared with non-users.

6PubMed Central. Statins and risk of type 2 diabetes: mechanism and clinical implications

This does not mean you should stop your statin. For most people at meaningful cardiovascular risk, the reduction in heart attacks and strokes vastly outweighs a modest bump in diabetes risk. But it does mean your doctor should be monitoring your blood sugar periodically, especially if you are already on the borderline or taking a high-intensity statin. The tradeoff is worth understanding rather than ignoring.

Antipsychotic Medications

The link between antipsychotic drugs and diabetes has been recognized for decades, and it is strongest with the so-called atypical antipsychotics. Not all drugs in this class carry the same risk. A study using a large health plan database found that after twelve months of exposure, olanzapine tripled the odds of developing type 2 diabetes compared with untreated patients. Clozapine showed an even higher point estimate, though with a wide confidence interval. Conventional (older-generation) antipsychotics also raised the risk, roughly doubling to tripling it depending on potency. Risperidone, by contrast, did not show a significant increase in that study.

7The Journal of Clinical Psychiatry. Differential Effects of Risperidone, Olanzapine, Clozapine, and Conventional Antipsychotics on Type 2 Diabetes

The diabetes risk with antipsychotics is partly driven by weight gain, since several of these drugs cause significant appetite increases and fat accumulation. But weight gain alone does not explain the full picture. Some antipsychotics appear to directly impair insulin signaling and glucose regulation independent of how much weight a person puts on. Olanzapine, for instance, showed a dose-dependent relationship with diabetes, meaning higher doses carried higher risk even when controlling for other factors.

For people with serious mental illness who need these medications, the practical question is whether an alternative antipsychotic with a lower metabolic profile could work just as well. That conversation is worth having with a psychiatrist, especially for patients who already carry diabetes risk factors.

Blood Pressure Medications

Two classes of blood pressure drugs have been linked to worsened glucose metabolism: thiazide diuretics and certain beta-blockers. They work through different mechanisms, and the risk level differs between them.

Thiazide diuretics like hydrochlorothiazide lower blood pressure partly by increasing the kidneys’ excretion of sodium and water, but they also push potassium out of the body. That potassium loss is directly tied to rising blood sugar. A quantitative review found a meaningful inverse relationship between potassium levels and glucose levels in patients taking thiazides: as potassium dropped, glucose went up. Correcting the low potassium with supplementation can reverse the glucose rise and may prevent the eventual slide into diabetes.

8Hypertension. Thiazide diuretics, potassium, and the development of diabetes: a quantitative review

Beta-blockers present a more mixed story. Older beta-blockers like metoprolol can reduce insulin sensitivity by about 14%, making it harder for your body to clear sugar from the bloodstream.

9PubMed. Differential effect of chronic treatment with two beta-blocking agents on insulin sensitivity: the carvedilol-metoprolol study Newer agents like carvedilol, which also relaxes blood vessels, have the opposite effect on glucose metabolism. A randomized trial comparing the two in patients with type 2 diabetes and high blood pressure found that carvedilol improved insulin resistance by about 9%, while metoprolol showed no meaningful change.

10JAMA. Metabolic Effects of Carvedilol vs Metoprolol in Patients With Type 2 Diabetes Mellitus and Hypertension

The practical takeaway here is that not all drugs within a class are equal. If you need a beta-blocker and you already have diabetes risk factors, the choice of which beta-blocker to use can make a metabolic difference. ACE inhibitors and ARBs, two other major blood pressure drug classes, do not carry the same glucose-raising concerns and are often preferred in patients with diabetes.

Immunosuppressants and Transplant Drugs

People who receive organ transplants are placed on powerful immunosuppressive drugs to prevent rejection, and diabetes after transplant is a recognized complication. The calcineurin inhibitors cyclosporine and tacrolimus both contribute to this problem through multiple pathways: they decrease insulin secretion, increase insulin resistance, and may directly damage the insulin-producing cells of the pancreas.

11PubMed. Post-transplant diabetes mellitus. The role of immunosuppression

Tacrolimus tends to be the worse offender of the two. Transplant patients often receive these drugs alongside glucocorticoids, creating a double hit on glucose metabolism. The combination is a major reason why diabetes rates among transplant recipients are so high, as noted earlier in the glucocorticoid section.

Another class of immunosuppressants, the mTOR inhibitors (drugs like sirolimus and everolimus), carry their own diabetes risk. These drugs are used in transplant medicine and increasingly in cancer treatment. They impair insulin signaling within cells and reduce the pancreas’s ability to secrete insulin.

12PubMed. mTOR and Cardiovascular Diseases: Diabetes Mellitus In cancer trials, the rate of new-onset diabetes with mTOR inhibitors has ranged from 13% to 50%, depending on the study.13PubMed. mTOR inhibitors and diabetes

Cancer Immunotherapy and a Different Kind of Diabetes

Immune checkpoint inhibitors, the newer cancer drugs that unleash the immune system against tumors, can trigger a form of diabetes that looks quite different from the type caused by steroids or antipsychotics. Rather than inducing gradual insulin resistance, these drugs can provoke the immune system to attack the insulin-producing beta cells in the pancreas, essentially triggering an autoimmune process similar to type 1 diabetes. The onset can be sudden and severe, sometimes presenting with diabetic ketoacidosis, a dangerous metabolic emergency.

14PubMed Central. Immune checkpoint inhibitor diabetes mellitus: a novel form of autoimmune diabetes

This form of drug-induced diabetes is relatively rare compared with, say, steroid-induced diabetes, but it is permanent. Once the beta cells are destroyed, they do not come back, and the patient typically needs insulin for life. Regular blood sugar monitoring during checkpoint inhibitor therapy reduces the proportion of patients who develop severe ketoacidosis.

15PubMed Central. Real-world adherence to toxicity management guidelines for immune checkpoint inhibitor-induced diabetes mellitus

HIV Protease Inhibitors

The antiretroviral drugs used to treat HIV, particularly the protease inhibitors that were central to early combination therapy, have a well-documented effect on glucose metabolism. Laboratory research showed that the protease inhibitor indinavir blocked insulin-stimulated glucose uptake by more than 60% in fat cells. The mechanism was surprisingly specific: these drugs directly inhibit the Glut4 glucose transporter, the main channel through which insulin-sensitive tissues absorb sugar from the blood.

16PubMed. The mechanism of insulin resistance caused by HIV protease inhibitor therapy

This effect was observed across multiple protease inhibitors, making it a class-wide problem rather than a quirk of one drug. The clinical consequence was a wave of insulin resistance, abnormal fat distribution, and diabetes in HIV patients during the era when protease inhibitors were standard therapy. Newer antiretroviral regimens have shifted toward drugs with better metabolic profiles, though some patients remain on older combinations for reasons of viral resistance or tolerance.

Androgen Deprivation Therapy

Men with prostate cancer who are treated with androgen deprivation therapy, which suppresses testosterone to slow tumor growth, face an increased risk of diabetes. The hormonal shift causes the body to gain fat mass, lose lean muscle, and become more resistant to insulin. This metabolic reshuffling can begin within the first few months of treatment.

17PubMed Central. Risk of Diabetes among Patients Receiving Primary Androgen Deprivation Therapy for Clinically Localized Prostate Cancer

The relationship between androgen deprivation and insulin resistance is well recognized, though the absolute risk of developing clinical diabetes depends on the patient’s baseline metabolic health and how long treatment continues.

18PubMed. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer For men already carrying excess weight or prediabetes, androgen deprivation can accelerate the timeline to a diabetes diagnosis. Exercise programs and dietary changes during treatment can blunt some of this metabolic impact, and oncologists increasingly factor cardiovascular and metabolic risk into treatment planning.

Who Is Most Vulnerable

Not everyone who takes a diabetogenic drug develops diabetes. The risk depends on a collision between the drug’s effects and the individual’s own metabolic vulnerabilities. The factors that tip the balance include obesity, pre-existing insulin resistance, a family history of diabetes, older age, and belonging to racial or ethnic groups with higher baseline diabetes rates. Taking multiple drugs that affect glucose at the same time compounds the problem, as does being under physical stress from illness or surgery.

19BMJ Publishing Group Ltd. Medication-induced hyperglycemia: pediatric perspective

This explains why two patients can take the same steroid course and have wildly different glucose outcomes. One might sail through with normal blood sugar while the other ends up needing insulin. The drug is the trigger, but the gun was already loaded by genetics, weight, and metabolic history.

Children and Adolescents at Risk

Drug-induced diabetes is not just an adult problem. An analysis of over 500,000 pediatric adverse-event reports submitted to the FDA identified nearly 2,500 cases of drug-induced high blood sugar or diabetes in children. About 72% of those cases occurred in adolescents aged 10 to 18. The most commonly implicated drug categories were cancer drugs, glucocorticoids, immunosuppressants, psychiatric medications, and growth hormone.

20PubMed Central. A real-world investigation of drug-induced hyperglycemia and diabetes mellitus in pediatric populations using the FDA adverse event reporting system

Children being treated for acute lymphoblastic leukemia, who typically receive both glucocorticoids and other chemotherapy agents, face a particularly elevated risk. Research on this population found that each additional year of age increased diabetes risk by about 39%, and girls were nearly three times as likely as boys to develop it. Involvement of the central nervous system in the disease further raised the odds.

21Blood. Drug-Induced Diabetes during Treatment of ALL in Children: Who Is at Risk and When?

These findings underscore the importance of glucose monitoring in children on high-risk drug regimens, particularly during adolescence when hormonal changes already strain insulin regulation.

Is Drug-Induced Diabetes Reversible

This is the question most people want answered, and the answer depends heavily on the type of drug and the mechanism at play. For many medications that cause diabetes through insulin resistance, such as glucocorticoids, statins, and antipsychotics, the blood sugar elevation can partly or fully reverse once the drug is stopped or the dose is lowered.

22PubMed. The impact of cardiovascular drugs on hyperglycemia and diabetes: a review of ‘unspoken’ side effects

But “can reverse” does not mean “always reverses.” If someone was already on the edge of diabetes before starting the medication, and the drug pushed them over, removing the drug may not be enough to restore normal glucose metabolism. The underlying vulnerability remains. And for checkpoint-inhibitor-induced diabetes, where the immune system destroys pancreatic beta cells, the damage is usually permanent regardless of whether the drug is continued.

The practical implication is that stopping a medication is not always realistic. Many of these drugs treat life-threatening or serious chronic conditions. The real strategy is managing the metabolic side effects while continuing the necessary treatment, through glucose monitoring, lifestyle adjustments, and sometimes adding diabetes medications alongside the offending drug.

When Fear of Side Effects Becomes Its Own Problem

There is a real tension in communicating these risks. Knowing that a statin or an antipsychotic can cause diabetes sometimes leads patients to stop taking medications they genuinely need. Research on medication adherence in type 2 diabetes has shown that concerns about long-term side effects are one of the drivers of prolonged non-adherence.

23PubMed. Trends of self-reported non-adherence among type 2 diabetes medication users in the United States across three years using the self-reported Medication Adherence Reasons Scale

The risk of developing diabetes from a statin is real but modest in absolute terms. The risk of having a heart attack or stroke without the statin, in someone who needs it, is substantially larger. Similarly, stopping an antipsychotic because of metabolic worries can lead to psychiatric relapse, hospitalization, and worse overall health outcomes. The smart approach is not to avoid these drugs out of fear but to go in with eyes open: ask your doctor about baseline glucose testing before starting a high-risk medication, get periodic blood work while on it, and address modifiable risk factors like diet, exercise, and weight that you can actually control. A drug that slightly raises your diabetes risk while keeping you alive and functional is usually a trade worth making, as long as someone is watching the numbers.